Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magnetic pulses to the brain may lift long COVID fog

NCT ID NCT07278206

Symptom relief Sponsor: Amsterdam UMC, location VUmc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a gentle brain stimulation technique called rTMS to see if it can reduce severe fatigue and concentration problems in people with long COVID. Researchers will give 66 adults either real or fake (placebo) stimulation over six weeks. The goal is to find a safe, non-drug treatment for these common long COVID symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 66 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Meet the World Health Organization (WHO) definition of long COVID. * Aged 18 years or older. * Severe fatigue, defined as a score ≥35 on the Checklist Individual Strength (CIS) fatigue subscale. * Significant cognitive complaints, defined as a score ≥18 on the CIS concentration subscale. * Commitment to actively undergo rTMS * Ability to attend the study site regularly for treatment sessions. * Capacity to provide written informed consent. Exclusion Criteria: * Prior rTMS treatment or current intensive/experimental treatment for long COVID. * History of epilepsy or first-degree family history of epilepsy. * Recent initiation or dosage change of psychotropic medication (less than six weeks for psychotropic medication including antidepressants and antipsychotic drugs, less than two weeks for benzodiazepines). Medication doses must remain stable during the study. * Other active concurrent pharmacological treatments for post-covid symptoms * Contraindications to MRI scanning (e.g., non-removable metallic implants, severe claustrophobia). * Presence of a cochlear implant. * Neurological disorders such as multiple sclerosis or other neurodegenerative conditions. * Pregnancy. * Known brain lesions or ischaemic scars influencing seizure threshold. * Severe uncontrolled migraines. * Severe cardiovascular disease * Raised intracranial pressure. * High alcohol consumption (males/females: 21/14 units per week) or use of epileptogenic drugs. * Severe sleep deprivation at the time of treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Long COVID are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

long COVID-19 post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Long COVID Pasc post acute sequelae of COVID-19 Post COVID-19 condition (PCC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam UMC

    RECRUITING

    Amsterdam, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.